false
0001734005
0001734005
2026-08-07
2026-08-07
0001734005
dei:FormerAddressMember
2026-08-07
2026-08-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 7, 2026
Niki BioSolutions, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware |
|
001-38764 |
|
42-3265309 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 116 Village Boulevard, Suite 200, Princeton, NJ 08540 |
| (Address of Principal Executive Offices, including zip code) |
Registrant’s Telephone Number, Including
Area Code: 609-951-2222
Aptorum Group Limited
17 Hanover Square
London W1S 1BN, United Kingdom
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, par value $0.0001 per share |
|
NIKI |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously reported,
on March 5, 2026, Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited) (the “Company”) received a deficiency letter from the Listing Qualifications
Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business
days, the closing price for the Company’s common stock had been below the minimum $1.00 per share required for continued
listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).
The letter also indicated
that the Company had a compliance period of 180 calendar days, or until September 1, 2026 (the “Compliance Period”), in which
to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter further provided that if, at anytime during the Compliance
Period, the Company’s common stock closed at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq would
provide the Company with written confirmation that it had achieved compliance with the minimum bid price requirement.
On August 4, 2026, the Company
received a letter from Nasdaq notifying the Company that for the last 10 consecutive business days, from July 21, 2026, to August 3, 2026,
the closing bid price of the Company’s common stock had been at $1.00 per share or greater and, therefore, the Company has regained
compliance with Nasdaq Listing Rule 5550(a)(2) and this matter is now closed.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 7, 2026
| |
NIKI BIOSOLUTIONS, INC. |
| |
|
|
| |
By: |
/s/ Ian Huen |
| |
|
Ian Huen |
| |
|
Chief Executive Officer |
2